JP2020522544A - Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 - Google Patents

Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 Download PDF

Info

Publication number
JP2020522544A
JP2020522544A JP2019567608A JP2019567608A JP2020522544A JP 2020522544 A JP2020522544 A JP 2020522544A JP 2019567608 A JP2019567608 A JP 2019567608A JP 2019567608 A JP2019567608 A JP 2019567608A JP 2020522544 A JP2020522544 A JP 2020522544A
Authority
JP
Japan
Prior art keywords
patient
antibody
antigen
binding fragment
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522544A5 (https=
Inventor
マーヤ・ブーヤス−ボバノヴィッチ
Original Assignee
サノフィ・バイオテクノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ・バイオテクノロジー filed Critical サノフィ・バイオテクノロジー
Priority claimed from PCT/IB2018/054182 external-priority patent/WO2018225041A1/en
Publication of JP2020522544A publication Critical patent/JP2020522544A/ja
Publication of JP2020522544A5 publication Critical patent/JP2020522544A5/ja
Priority to JP2023111915A priority Critical patent/JP2023123842A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2019567608A 2017-06-09 2018-06-09 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 Pending JP2020522544A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023111915A JP2023123842A (ja) 2017-06-09 2023-07-07 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762517672P 2017-06-09 2017-06-09
US62/517,672 2017-06-09
US201762532162P 2017-07-13 2017-07-13
US62/532,162 2017-07-13
EP18305565 2018-05-04
EP18305565.6 2018-05-04
PCT/IB2018/054182 WO2018225041A1 (en) 2017-06-09 2018-06-09 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023111915A Division JP2023123842A (ja) 2017-06-09 2023-07-07 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法

Publications (2)

Publication Number Publication Date
JP2020522544A true JP2020522544A (ja) 2020-07-30
JP2020522544A5 JP2020522544A5 (https=) 2021-07-26

Family

ID=62815099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567608A Pending JP2020522544A (ja) 2017-06-09 2018-06-09 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法
JP2023111915A Pending JP2023123842A (ja) 2017-06-09 2023-07-07 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023111915A Pending JP2023123842A (ja) 2017-06-09 2023-07-07 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法

Country Status (9)

Country Link
EP (1) EP3634469A1 (https=)
JP (2) JP2020522544A (https=)
KR (1) KR20200026826A (https=)
CN (1) CN110913889A (https=)
AU (1) AU2018280567A1 (https=)
CA (1) CA3066317A1 (https=)
IL (2) IL271212B2 (https=)
MX (1) MX2019014831A (https=)
TW (2) TW202310872A (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
CN113876956B (zh) * 2020-07-01 2023-07-04 陈敏 Pcsk9抑制剂在制备促进皮肤色素生成产品中的应用
CN114525258A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达pcsk9阻断物的多能干细胞或其衍生物及应用
CN120272480A (zh) * 2021-09-30 2025-07-08 北京安龙生物医药有限公司 用于治疗与pcsk9相关疾病的靶向寡核苷酸
CN116236582A (zh) * 2021-12-07 2023-06-09 广州嘉越医药科技有限公司 吲哚取代四氢异喹啉类化合物与他汀类化合物的联合应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2015140079A1 (en) * 2014-03-17 2015-09-24 Sanofi Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
RU2723018C2 (ru) * 2014-07-16 2020-06-08 Санофи Байотекнолоджи Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
PL3169353T3 (pl) * 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
JP2018523684A (ja) * 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIRK MULLERWIELAND, CARDIOVASC.DIABETOL, vol. VOL:16,NR:70, JPN5020007003, 25 May 2017 (2017-05-25), ISSN: 0004812357 *
HELEN M COLHOUN: "NO EFFECT OF PCSK9 INHIBITOR ALIROCUMAB ON THE INCIDENCE OF DIABETES IN A POOLED 以下備考", EUROPEAN HEART JOURNAL, vol. VOL:37, NR:39, JPN5020007004, 26 July 2016 (2016-07-26), pages 2981 - 2989, ISSN: 0004812358 *
LAWRENCE A LEITER: "LIPID-LOWERING EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH OR WITHOUT DIABETES: 以下備考", DIABETES, OBESITY AND METABOLISM, vol. VOL:19, NR:7, JPN5020007002, 16 February 2017 (2017-02-16), pages 989 - 996, ISSN: 0005005944 *

Also Published As

Publication number Publication date
IL271212B1 (en) 2024-08-01
KR20200026826A (ko) 2020-03-11
TW202310872A (zh) 2023-03-16
EP3634469A1 (en) 2020-04-15
IL271212A (en) 2020-01-30
CN110913889A (zh) 2020-03-24
IL314423A (en) 2024-09-01
RU2019144346A (ru) 2021-07-09
RU2019144346A3 (https=) 2021-10-13
IL271212B2 (en) 2024-12-01
AU2018280567A1 (en) 2020-01-23
TW201904608A (zh) 2019-02-01
MX2019014831A (es) 2020-02-13
CA3066317A1 (en) 2018-12-13
JP2023123842A (ja) 2023-09-05

Similar Documents

Publication Publication Date Title
US20190031774A1 (en) Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
JP2023123842A (ja) Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法
JP7789871B2 (ja) グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
EP3055333B1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
EP3331908B1 (en) Anti-angptl8 antibodies and uses thereof
JP2022169718A (ja) Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
AU2014274077B2 (en) Methods for treating autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function mutations
KR102482375B1 (ko) 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
JP2017506626A (ja) 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法
US20230272112A1 (en) Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
RU2772712C2 (ru) Способы лечения гиперлипидемии у пациентов с диабетом посредством введения ингибитора pcsk9
ES2779126T3 (es) Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
HK40033729B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK40033729A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA045412B1 (ru) Агонисты рецептора глюкагоноподобного пептида 1 и их применения
HK1227890B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890A1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230307